Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan.

ABSTRACT: In Japan, 1.5-2 million people are chronically infected with hepatitis C virus (HCV) infection. New direct-acting antiviral agents (DAA) offer an unprecedented opportunity to cure HCV. While the price of HCV treatment decreased recently in most countries, it remains one of the highest in Japan. Our objective was to evaluate the cost-effectiveness of HCV treatment in patients of different age groups and to estimate the price at which DAAs become cost-saving in Japan. A previously developed microsimulation model was adapted to the Japanese population and updated with Japan-specific health utilities and costs. Our model showed that compared with no treatment, the incremental cost-effectiveness ratio (ICER) of DAAs at a price USD 41,046 per treatment was USD 9,080 per quality-adjusted life yea

SUBMITTER: Zhuo Y 

PROVIDER: S-EPMC7058050 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature